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Abstract
Background: Current study was designed to investigate the effects of obstructive sleep apnea (OSA) combined
dyslipidemia on the prevalence of atherosclerotic cardiovascular diseases (ASCVD).
Methods: This was a cross-sectional study and subjects with documented dyslipidemia and without previous
diagnosis of OSA were enrolled. Polysomnography was applied to evaluate apnea-hypopnea index (AHI). Based on
AHI value, subjects were classified into four groups: without OSA, mild, moderate and severe OSA groups. Clinical
characteristics and laboratory examination data were recorded. Relationship between AHI event and lipid profiles
was analyzed, and logistic regression analysis was used to evaluate the effects of OSA combined dyslipidemia on
ASCVD prevalence.
Results: Totally 248 subjects with dyslipidemia were enrolled. Compared to the other 3 groups, subjects with
severe OSA were older, male predominant and had higher smoking rate. In addition, subjects with severe OSA had
higher body mass index, waist-hip ratio, blood pressure, and higher rates of overweight and obesity. Serum levels
of fasting plasma glucose, glycated hemoglobin, LDL-C and CRP were all significantly higher. ASCVD prevalence
was considerably higher in subjects with severe OSA. AHI event in the severe OSA group was up to 35.4 ± 5.1
events per hour which was significantly higher than the other groups (P < 0.05 for trend). Pearson correlation
analysis showed that only LDL-C was positively correlated with AHI events (r = 0.685, P < 0.05). Logistic regression
analysis revealed that in unadjusted model, compared to dyslipidemia plus no-OSA group (reference group), OSA
enhanced ASCVD risk in subjects with dyslipidemia, regardless of OSA severity. After extensively adjusted for
confounding variables, the odds of dyslipidemia plus mild-OSA was reduced to insignificance. While the effects of
moderate- and severe-OSA on promoting ASCVD risk in subjects with dyslipidemia remained significant, with
severe-OSA most prominent (odds ratio: 1.52, 95 % confidence interval: 1.13–2.02).
Conclusion: OSA combined dyslipidemia conferred additive adverse effects on cardiovascular system, with
severe-OSA most prominent.
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Background
Obstructive sleep apnea (OSA) which is featured by inter-
mittent hypoxemia during sleep is associated with athero-
sclerotic cardiovascular diseases (ASCVD) as revealed by
previous epidemiological researches [1–3]. Owing to the
increased pandemic of obesity [4, 5], a major risk factor of
OSA, the incidence and prevalence of OSA is increased
dramatically in recent decades [6]. Therefore, it is clinic-
ally relevant and important to screen, diagnose and treat
OSA timely so as to reduce the ASCVD risk.
Dyslipidemia, as mainly defined by increased serum
total cholesterol (TC) and low density lipoprotein chol-
esterol (LDL-C) levels, is another major risk of ASCVD.
And a substantial amount of epidemiological and inter-
ventional researches have consistently demonstrated a
linear relationship between serum LDL-C level and
incident ASCVD [7]. In brief, LDL-C elevation is largely
associated with increased consumption of saturated fat,
which could also lead to central adiposity and obesity
[8]. Therefore, it is conceivable that obesity may play
overlapped roles between OSA and dyslipidemia, and
OSA plus dyslipidemia may confer additive adverse ef-
fects on cardiovascular system. However, the evidence is
lacking.
In our present cross-sectional research, we initially in-
vestigated the relationship between index of OSA and
serum lipid profiles, and then evaluated the effects of
OSA plus dyslipidemia on the prevalence of ASCVD.
We hoped that information from our current study
would broaden our understanding about the effects of
OSA plus dyslipidemia on cardiovascular system, and
additionally provide basics and insights for future clin-
ical studies in managing OSA and dyslipidemia effect-
ively so as to further reduce ASCVD risk.
Methods
Studied subjects enrollment
Present study was approved by the ethic committee of
Shanghai Changzheng Hospital. Subjects were enrolled
after informed consent was obtained, and the time of
enrollment was from October of 2014 to October of 2015.
All subjects had not been previously diagnosed as OSA, but
were diagnosed as dyslipidemia according to self-
report, or treatment with statins, or increased serum
TC and/or LDL-C level.
Clinical characteristics and laboratory data collection
Clinical characteristics including age, gender, smoking
status, height and weight for calculating body mass index
(BMI), waist and hip circumference for calculating waist-
hip ratio, systolic/diastolic blood pressure (SBP/DBP) and
heart rate (HR) at rest were recorded in electronic case re-
port form. ASCVD included previously diagnosed as coron-
ary heart disease (CHD), ischemic stroke and peripheral
artery disease (PAD) based on clinical symptoms plus ob-
jective evidence such as coronary angiography, computer
tomography scan and Doppler ultrasound. Medical history
and medicine usages were also collected. Laboratory data
included fasting lipid profiles and plasma glucose (FPG),
glycated hemoglobin (HbA1c) and C-reactive protein
(CRP) were collected and double-checked by two working
staffs.
OSA diagnosis with polysomnography
All enrolled subjects were underwent attended polysomno-
graphy and based on apnea-hypopnea index (AHI), those
with AHI ≥ 5 events per hour were diagnosed as OSA [9].
In brief, AHI with 5–14.9 was defined as mild, 15–29.9
moderate and ≥ 30 severe, and less than 5 was without
OSA.
Statistical analysis
Continuous variables are presented with mean and SD and
categorical variables are presented with the number and
percentages. Statistical significance of differences is ana-
lyzed using one-way ANOVA or Mann–Whitney U test for
continuous variables and the chi-square or Fisher exact test
for categorical variables. Pearson correlation analysis was
performed to evaluate the relationship between AHI and
lipid profiles. Logistic regression analysis was applied to cal-
culate odds ratio (OD) and associated 95 % confidence in-
tervals (CI) of OSA plus dyslipidemia on ASCVD
prevalence. Statistical analysis is computed using SPSS 16.0
(SPSS Inc, Chicago, IL). All of the statistical tests were two-
sided and considered statistically significant if P < 0.05.
Results
Comparisons of clinical characteristics
Totally, 248 subjects with dyslipidemia were enrolled,
and according to the severity of OSA, all subjects were
classified into four groups as presented in Table 1. Com-
pared to the other three groups, subjects in the severe
OSA group were older, male predominant and had
higher rate of smoking (P <0.05 for trend). Furthermore,
subjects with severe OSA appeared to at correspondingly
higher prevalence of OSA risk factors as reflected by
higher BMI, waist-hip ratio, blood pressure, and higher
rates of overweight and obesity (P <0.05 for trend). With
respect to laboratory examination, serum levels of FPG,
HbA1c, LDL-C and CRP were all significantly higher in
severe OSA group (P <0.05 for trend). ASCVD preva-
lence including CHD, ischemic stroke and PAD was also
considerably higher in subjects with severe OSA, and
higher rates of medicines application might reflect the
higher ASCVD risk (P <0.05 for trend). All these data
revealed a linear relationship between OSA severity and
ASCVD risk. AHI event in the severe OSA group was
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up to 35.4 ± 5.1 events per hour which was significantly
higher than the other groups (P <0.05 for trend).
Relationship between lipid profiles and AHI events
Pearson correlation analysis was applied to evaluate the
relationship between serum TC, TG, LDL-C and HDL-C
levels and AHI events. As shown in Table 2 and Fig. 1
that only LDL-C were positively correlated with AHI
events, with correlation coefficient was 0.685 (P < 0.05).
And the other lipid indices were not significantly corre-
lated with AHI events.
Effects of OSA plus dyslipidemia on ASCVD prevalence
Logistic regression analysis was used to analyze the effects
of OSA plus dyslipidemia on ASCVD prevalence. As shown
in Table 3, in the unadjusted model, compared to the
dyslipidemia plus no-OSA group (reference group), OSA
enhanced ASCVD risk in subjects with dyslipidemia,
regardless of OSA severity. After adjusted for age, gender,
BMI and waist-hip ratio (model 1), the odds of dyslipidemia
plus mild-OSA on increasing ASCVD prevalence was re-
duced to insignificance. While the effects of moderate-OSA
and severe-OSA on promoting ASCVD risk in subjects
with dyslipidemia remained significant. Additional adjusted
for SBP, FPG, LDL-C, CRP and statins (model 2), the effect
of moderate-OSA and severe-OSA on enhancing ASCVD
risk was still significant, with severe-OSA most prominent
(OR: 1.52, 95 % CI: 1.13–2.02).
Table 1 Comparisons of clinical characteristics
Variables Without OSA Mild Moderate Severe
N 56 74 65 53
Age (years) 49.4 ± 11.6 52.2 ± 13.6 53.3 ± 12.2 55.3 ± 13.1*
Male, n (%) 30(53.6) 41(55.4) 35(53.8) 31(58.5)*
Smoking, n (%) 24(42.9) 37(50.0) 32(49.2) 28(52.8)*
BMI (Kg/m2) 24.2 ± 2.7 25.5 ± 3.5 25.8 ± 4.6 26.3 ± 3.9*
Overweight, n (%) 10(17.9) 30(40.5) 31(47.7) 27(50.9)*
Obesity, n (%) 0(0) 0(0) 3(4.6) 8(15.1)*
Waist-hip ratio 0.90 ± 0.03 0.92 ± 0.05 0.94 ± 0.04 0.96 ± 0.03*
SBP (mm Hg) 132.5 ± 10.2 131.7 ± 12.3 135.8 ± 11.6 138.2 ± 13.4*
DBP (mm Hg) 73.6 ± 8.8 73.2 ± 10.5 77.3 ± 9.1 81.2 ± 10.6*
HR (bpm) 74.2 ± 6.6 80.4 ± 9.2 88.4 ± 9.2 93.6 ± 11.2*
FPG (mmol/L) 6.0 ± 1.1 6.2 ± 1.7 6.4 ± 1.5 6.7 ± 1.6*
HbA1c (%) 6.0 ± 1.3 6.3 ± 1.3 6.6 ± 1.3 6.8 ± 1.5*
TC (mmol/L) 5.3 ± 0.5 5.3 ± 0.4 5.4 ± 0.5 5.5 ± 0.6
TG (mmol/L) 1.3 ± 0.4 1.4 ± 0.4 1.4 ± 0.3 1.5 ± 0.4
LDL-C (mmol/L) 3.1 ± 0.4 3.3 ± 0.4 3.3 ± 0.3 3.5 ± 0.5*
HDL-C (mmol/L) 1.0 ± 0.3 0.9 ± 0.3 0.8 ± 0.3 0.8 ± 0.4
CRP (mg/L) 9.2 ± 1.2 10.8 ± 2.4 12.7 ± 2.6 14.2 ± 3.3*
CHD, n (%) 6(10.7) 10(13.5) 11(16.9) 10(18.9)*
Ischemic stroke, n (%) 3(5.4) 4(5.4) 6(9.2) 6(11.3)*
PAD, n (%) 3(5.4) 3(4.1) 4(6.2) 5(9.4)*
Anti-platelet, n (%) 22(39.3) 34(45.9) 32(49.2) 28(52.8)*
ACEI/ARB, n (%) 26(46.4) 36(48.6) 34(52.3) 29(54.7)*
Statins, n (%) 29(51.8) 37(50.0) 35(53.8) 31(58.5)*
AHI (events/h) 3.2 ± 1.3 12.6 ± 2.3 21.2 ± 3.3 35.4 ± 5.1*
Denote: *P < 0.05 versus other groups; bpm beat per minute, TG triglyceride, HDL-C high density lipoprotein cholesterol, ACEI angiotensin converting enzyme
inhibitor, ARB angiotensin receptor blocker
Table 2 Relationship between lipid profiles and AHI events
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Discussion
Dyslipidemia and OSA both are major risk factors of
ASCVD, and theoretically these two co-morbidities may
confer additional risk on ASCVD. Data from our current
study support this concept. We observe that there is a
linear relationship between OSA severity and cardiovas-
cular risk profiles in subjects with documented dyslipid-
emia; secondly, there is a positive correlation between
serum LDL-C level and AHI events; thirdly, logistic
regression analysis shows that dyslipidemia plus OSA
confer additive effect on increasing ASCVD prevalence,
with severe-OSA most prominent.
With increasing pandemic of obesity, OSA has now
become more prevalent and imposes great public health
burden owing to its close association with ASCVD.
Mechanistically, through high-frequency intermittent
hypoxemia and arousals, OSA elicits systemic inflamma-
tion, oxidative stress, sympathetic nerve activation and
endothelial dysfunction [10–12]. All these pathological
changes are detrimental to cardiovascular system. In-
deed, a substantial amount of epidemiological studies
have showed that OSA is independently associated with
cardiovascular events. For example, Gottlieb DJ et al.
reported that OSA was a significant predictor of incident
Fig. 1 Relationship between lipid profiles and AHI events
Table 3 Effects of OSA plus dyslipidemia on ASCVD prevalence
Model Dyslipidemia + no-OSA Dyslipidemia + mild-OSA Dyslipidemia + moderate-OSA Dyslipidemia + severe-OSA
Unadjusted 1 1.54(1.16–2.07)* 1.77(1.42–2.24)* 1.96(1.35–2.62)*
Mode l 1 1.27(0.89–1.84) 1.36(1.07–1.86)* 1.84(1.29–2.33)*
Mode 2 1 1.09(0.81–1.77) 1.11(0.92–1.75)* 1.52(1.13–2.02)*
Denote: *P < 0.05
Model 1 adjusted for age, gender, BMI and waist-hip ratio
Model 2 adjusted for age, gender, BMI, waist-hip ratio, SBP, FPG, LDL-C, CRP and statins
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CHD and heart failure in community-dwelling middle-
aged and older men [13]. In another epidemiological
study, Punjabi NM and colleagues had demonstrated
that OSA was associated with all-cause mortality espe-
cially that ascribed to CHD [14]. Moreover, Redline S
and coworkers also had revealed that there was a strong
association between AHI event and ischemic stroke in
community-dwelling men with mild to moderate sleep
apnea [15]. All these evidence collectively supports the
notion that OSA increases risk of ASCVD.
Other than OSA, obesity is also closely associated with
dyslipidemia. And the adverse effects of dyslipidemia,
especially in subjects with obesity, on cardiovascular
system have been consistently demonstrated in previous
clinical researches [16, 17]. Nonetheless, whether OSA
could enhance the detrimental effects of dyslipidemia on
cardiovascular system is not fully clear yet. We therefore
conducted an observational research with cross-sectional
design to evaluate the effects of OSA plus dyslipidemia on
ASCVD prevalence. In brief, subjects with documented
dyslipidemia were enrolled and classified into four groups
based on OSA degree in order to evaluate the variable
effects of different OSA degree plus dyslipidemia on
ASCVD prevalence. In unadjusted model, OSA, regardless
of severity, rendered additional risk of ASCVD in subjects
with documented dyslipidemia. Nevertheless, after exten-
sively adjusted for potential confounding variables, only
moderate-OSA and severe-OSA still had significant effects
on increasing odds of ASCVD in subjects with dyslipid-
emia. To our best knowledge, the following aspects might
partially explain these findings. On the one hand, the ef-
fects of mild-OSA which was reduced to insignificant
might be due to the modest effect of OSA on cardiovascu-
lar system. Some previous epidemiological studies showed
that only moderate or severe OSA had independent effects
on cardiovascular system, which might support this specu-
lation. On the other hand, it was reported that high-
frequency intermittent hypoxemia contributed to dyslipid-
emia [18]. Therefore, severe OSA might further elevate
serum LDL-C level and exaggerate the adverse effects re-
lated to dyslipidemia. Data from between-group compari-
son also supported this speculated as reflected by
significantly higher serum LDL-C level in severe-OSA
group compared to other groups. Last but not the least,
since both OSA and dyslipidemia are associated with sys-
temic inflammation as reflected by increased serum CRP
level [19, 20]. And it had been demonstrated that in-
creased serum CRP level is associated with increased risk
of ASCVD [21]. Therefore, through concurrently increas-
ing serum CRP level, dyslipidemia plus OSA might en-
hance ASCVD risk in an OSA-severity dependant
manner.
There were some limitations of current study meriting
address here. Firstly, the nature of cross-sectional design
could not allow us to draw causal relationship between
OSA plus dyslipidemia and ASCVD prevalence. Sec-
ondly, relative small sample size might not allow us to
identify other potential differences between groups.
Thirdly, despite extensively adjusted for potential con-
founding variables, the unrecognized biases regarding
our findings still could not be ruled out.
Conclusion
Our preliminary research showed that OSA increased
ASCVD prevalence in subjects with documented dyslipid-
emia, and OSA plus dyslipidemia conferred additive
adverse effects on cardiovascular system, with severe-OSA
most prominent. In the future study, it is warranted to
investigate whether improve OSA could reduce ASCVD
risk associated with dyslipidemia.
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